摘要
目的探讨白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效和安全性。方法回顾性收集2016年5月至2018年4月于首都医科大学大兴医院应用含白蛋白结合型紫杉醇方案化疗的经多线治疗后复发的晚期肿瘤患者的临床资料,评估疗效和安全性。结果共纳入36例晚期难治性肿瘤患者,所有患者均可进行疗效评估,既往接受过含普通紫杉醇化疗的患者为20例(55.56%)。患者的客观有效率(ORR)为8.33%,疾病控制率(DCR)为25.0%,中位无进展生存期(PFS)为106d,中位总生存期(OS)为183 d。3~4级的不良反应主要是血液学毒性,包括中性粒细胞减少发生率为36.11%(13/36),未出现粒细胞缺乏性发热的患者,贫血、血小板减少的发生率分别为5.56%(2/36)和16.67%(6/36),所有的患者均未发生3~4级非血液学毒性。结论含白蛋白结合型紫杉醇的化疗方案在多线治疗失败的晚期难治性恶性肿瘤中的疗效较好,且毒副作用可耐受。
Objective To investigate the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignant tumors.Methods Patients in advanced stage of cancer who had had drug-resistant relapse after receiving multiple-line treatment received chemotherapy with albumin-bound paclitaxel from May 2016 to April 2018 in Daxing Hospital of Capital Medical University.Their clinical data were collected to evaluate the treatment efficacy and safety profile.Results 36 patients who had advanced treatment-resistent tumors with evaluable data were enrolled.Of 36 patients,55.56%(20)had previously received chemotherapy with paclitaxel.The objective response rate(ORR)was 8.33%,the disease control rate(DCR)was 25.0%,the median progression free survival(PFS)was 106 days,and the median overall survival(OS)was 183 days.The main adverse reactions of grade 3-4 were hematological toxicity,including neutropenia[36.11%(13/36)],anemia and thrombocytopenia[5.56%(2/36)and 16.67%(6/36)]in patients without neutropenia fever.Adverse effects of 3-4 degrees related to non-hematologic toxicity were not observed.Conclusions Chemotherapy regimen with albumin-bound paclitaxel has certain efficacy for advanced malignant tumors resistant to multiple lines of therapy and the adverse effects could be generally tolerated.
作者
李文文
韩磊
张志国
李莉
郭宏伟
荀培
罗健
Li Wenwen;Han Lei;Zhang Zhiguo;Li Li;Guo Hongwei;Xun Pei;Luo Jian(Department of Oncology,Daxing Hospital of Capital Medical Iniversity,Beijing 102600,China;Department of Oncology,Chinese Academy of Medical Sciences(CAMS),Peking Union Medical College(PUMC),Cancer Hospital,Beijing 100021,China)
出处
《中国医师杂志》
CAS
2019年第12期1803-1807,共5页
Journal of Chinese Physician
关键词
白蛋白结合型紫杉醇
抗肿瘤联合化疗方案
抗药性
肿瘤
Albumin-bound paclitaxel
Antineoplastic combined chemotherapy protocols
Drug resistance,neoplasm
